The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThermo Fisher Scientific has agreed to divest its microbiology business unit to European private equity firm Astorg for $1.075 billion. The unit generated $645 million in revenue during 2025, and Thermo Fisher aims to use the sale proceeds to generate additional capital for enhancing shareholder value. The transaction is expected to close in the second half of 2026 and may be slightly dilutive to adjusted earnings per share in the first full year. Astorg plans to establish the business as an independent platform, focusing on operational enhancements and accelerated organic growth. Additionally, the private equity firm intends to pursue further M&A opportunities to expand the new platform's reach. Completion of the deal remains subject to customary regulatory approvals and closing conditions.